Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07287800 · ClinicalTrials.gov registry record · Phase 1

TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation

A Phase 1 study of Kidney Transplant and Hypogonadism, Male, sponsored by University of California, Los Angeles.

Active
Registry status
Phase 1
Development phase
50
Enrollment target
1
Study location

NCT07287800: Active Phase 1 study of Kidney Transplant and Hypogonadism, Male, sponsored by University of California, Los Angeles.

NCT07287800 is a Phase 1 study of Kidney Transplant and Hypogonadism, Male that is active but no longer recruiting, run by University of California, Los Angeles. The registered enrollment target is 50 participants, below the 1,897-participant average among 30 other Kidney Transplant trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07287800, a Phase 1 study of Kidney Transplant and Hypogonadism, Male, is active but no longer recruiting, sponsored by University of California, Los Angeles.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This prospective study aims to evaluate the safety and efficacy of testosterone replacement therapy (TRT) as an adjunct to an enhanced recover after surgery (ERAS) protocol in men with end-stage renal disease (ESRD) undergoing kidney transplantation. Participants will be highly-listed hypogonadal men, defined as total testosterone level \<300 on two occasions with clinical symptoms of hypogonadism, with ESRD who are expected to receive a kidney transplant within 6 months. Participants will be started on TRT, ideally for at least 3 months prior transplantation. The investigators will perform a subset analysis to evaluate if there is a significant difference in our endpoints by comparing these two subgroups (Three months or more receiving TRT vs. Less than three months receiving TRT). There will be no cut-off time for pre-transplant TRT. Following the intervention period, a historical control cohort of age-matched and health-matched patients will be identified, who have followed a standard transplant protocol that does not incorporate TRT. The primary outcome will evaluate safety, including 30- and 90-day adverse events, 3, 6, and 12-month allograft survival, and overall patient survival. Secondary outcomes will focus on (1) qualitative assessments of symptoms using validated questionnaires, (2) quantitative improvements in the hormonal profile before and after initiation of TRT and surgery, and (3) allograft function and incidence of delayed graft function. The results of this study could provide novel insights into the benefits of TRT in improving surgical outcomes in men with ESRD undergoing kidney transplantation.

Primary Outcome

Complications categorized by the CTCAE classification (grades 1-5)

Conditions Studied

Kidney Transplant Hypogonadism, Male End Stage Renal Disease (ESRD)

Interventions

  • DRUG Testosterone Replacement Therapy

Study Locations (1)

California

  • University of California, Los Angeles - Los Angeles

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-07-01
Est. Completion 2027-06
Phase Phase 1
University of California, Los Angeles

897 total trials

What the registry record for NCT07287800 still lists

NCT07287800 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,897-participant average among 30 other Kidney Transplant trials with a reported enrollment target (97% lower).

The record links to 3 conditions, with Kidney Transplant appearing as the primary indexed condition, and to 1 intervention - of which Testosterone Replacement Therapy is the first listed.

NCT07287800 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT07287800 about?

NCT07287800 is a clinical study titled "TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation". This prospective study aims to evaluate the safety and efficacy of testosterone replacement therapy (TRT) as an adjunct to an enhanced recover after surgery (ERAS) protocol in men with end-stage renal disease (ESRD) undergoing kidney transplantation. Participants will be highly-listed hypogonadal m...

What is the current status of trial NCT07287800?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2025-07-01. Estimated completion is 2027-06.

What conditions does trial NCT07287800 study?

This clinical trial studies the following conditions: Kidney Transplant, Hypogonadism, Male, End Stage Renal Disease (ESRD).

What interventions are being tested in trial NCT07287800?

The interventions under investigation include: Testosterone Replacement Therapy (DRUG).

Who is sponsoring clinical trial NCT07287800?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07287800 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Kidney Transplant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07287800's enrollment target sits among peer trials

50 18th of 30 higher than 13 of 30 other Kidney Transplant trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Kidney Transplant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT07287800, the US trial registry maintained by the National Library of Medicine. NCT07287800 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.